United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
314.12
-8.82 (-2.73%)
Mar 18, 2025, 4:00 PM EST - Market closed
United Therapeutics Revenue
In the year 2024, United Therapeutics had annual revenue of $2.88B with 23.63% growth. United Therapeutics had revenue of $735.90M in the quarter ending December 31, 2024, with 19.72% growth.
Revenue (ttm)
$2.88B
Revenue Growth
+23.63%
P/S Ratio
5.07
Revenue / Employee
$221,338,462
Employees
13
Market Cap
14.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.88B | 549.90M | 23.63% |
Dec 31, 2023 | 2.33B | 391.20M | 20.20% |
Dec 31, 2022 | 1.94B | 250.80M | 14.88% |
Dec 31, 2021 | 1.69B | 202.20M | 13.63% |
Dec 31, 2020 | 1.48B | 34.50M | 2.38% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
UTHR News
- 14 days ago - United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025 - Business Wire
- 20 days ago - United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 21 days ago - United Therapeutics: A Unique Business With High Margins And Expansion Potential - Seeking Alpha
- 22 days ago - United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 27 days ago - United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025 - Business Wire
- 6 weeks ago - United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis - Business Wire
- 6 weeks ago - United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial - Business Wire